Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call.
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024. Second Quarter and Recent Highlights: Total revenue increased 17% to $13.5 million Gross profit of $6.1 million; margin of 45% Net income of approximately $730,000 Adjusted EBITDA of $1.1 million Development of new data revenue stream First Half 2025 Highlights: Total revenue increased 14% to $27.6 million Gross profit of $13.1 million; margin of 47% Net income of $2.1 million Adjusted EBITDA of $3.2 million Ronnie Morris, CEO of Champions, commented, "Our second quarter's performance solidified our confidence in the Company's turnaround that we've been discussing the last several quarters.
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology Announces Agreement with Weill Cornell Medicine
HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing (CTL), part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncology to distribute and commercialize Weill Cornell Medicine's extensive bank of hematological patient-derived xenograft (PDX) models, generated by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at the institution and a member of the Englander Institute for Precision Medicine and Sandra and Edward Meyer Cancer Center.
Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2025 Earnings Conference Call September 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2025 Earnings Call.
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024. First Quarter Highlights: Total revenue increased 12% to $14.1 million Margin improved to 50% Adjusted EBITDA of $2.0 million Net income of $1.3 million Ronnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger.
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024. Fourth Quarter Financial Highlights: Fourth quarter revenue increased 7% to $14 million Adjusted EBITDA fourth quarter income of $884,000 Fourth quarter gross margin on pharmacology services of 49% Fiscal Year 2024 Financial Highlights: Annual revenue of $50.2 million, a decrease of 7% year-over-year Fiscal Year 2024 adjusted EBITDA loss of $3.9 million Fiscal Year 2024 gross margin on pharmacology services of 42% Ronnie Morris, CEO of Champions, commented, "As we discussed over the year, we'd be facing hurdles during fiscal 2024 due to the challenging funding environment in the biotech sector and a range of spending patterns from our larger pharmaceutical companies, leading to a slowdown in sales growth and an increase in cancellations.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
